Aging and cerebrovascular dysfunction: Contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy

Annals of the New York Academy of Sciences

Volumn 1207, Issue , 2010, Pages 58-70

  Vasilevko, Vitaly ^a   Passos, Giselle F ^a   Quiring, Daniel ^a   Head, Elizabeth ^a,b   Kim, Richard C ^a   Fisher, Mark ^b   Cribbs, David H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Blood brain barrier; Cerebral amyloid angiopathy; Hypertension; Immunotherapy

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; BAPINEUZUMAB; CYSTATIN C; GELSOLIN; PRION PROTEIN;

AGING; ALZHEIMER DISEASE; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; DISEASE ASSOCIATION; HIPPOCAMPAL CA1 REGION; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INCIDENCE; INFLAMMATION; MORTALITY; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT; VASCULAR AMYLOIDOSIS; ANIMAL; BLOOD BRAIN BARRIER; BRAIN ATHEROSCLEROSIS; DRUG ANTAGONISM; IMMUNOLOGY; PHYSIOLOGY;

AGING; AMYLOID BETA-PROTEIN; ANIMALS; BLOOD-BRAIN BARRIER; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL HEMORRHAGE; HUMANS; HYPERTENSION; IMMUNOTHERAPY; INTRACRANIAL ARTERIOSCLEROSIS;

EID: 78149274971     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05786.x     Document Type: Review

References (124)

1. Kalaria, R.N. 2009. Linking cerebrovascular defense mechanisms in brain ageing and Alzheimer's disease. Neurobiol. Aging 30: 1512-1514.
2. Iadecola, C., L. Park & C. Capone. 2009. Threats to the mind: aging, amyloid, and hypertension. Stroke 40: S40- S44.
3. Knopman, D.S. et al. 2005. Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology 65: 876-881.
4. Casserly, I. & E. Topol. 2004. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363: 1139-1146.
5. Deane, R. et al. 2004.LRP/amyloid beta-peptide interaction mediates differential brain efflux ofAbeta isoforms. Neuron 43: 333-344.
6. Zlokovic, B.V. 2008. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178- 201.
7. Carare,R.O. et al. 2008. Solutes, butnot cells, drain fromthe brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol. Appl. Neurobiol. 34: 131-144.
8. Weller, R.O. et al. 2008. Perivascular drainage of amyloidbeta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol. 18: 253-266.
9. Weller, R.O. et al. 2009. Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res. Ther. 6: art. 306.
10. Clapham, R. et al. 2010. Cervical lymph nodes are found in direct relationship with the internal carotid artery: significance for the lymphatic drainage of the brain. Clin. Anat. 23: 43-47.
11. Eng, J.A. et al. 2004. Clinical manifestations of cerebral amyloid angiopathy-relatedinflammation.Ann.Neurol. 55: 250-256.
12. Grabowski, T.J. et al. 2001. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol. 49: 697- 705.
13. Chui, H.C. et al. 2006. Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann. Neurol. 60: 677-687.
14. Selnes, O.A. & H.V. Vinters. 2006. Vascular cognitive impairment. Nat. Clin. Pract. Neurol. 2: 538-547.
15. McGeer, P.L., J. Rogers & E.G., McGeer. 2006. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J. Alzheimers Dis. 9: 271-276.
16. Huang, J. et al. 1999. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 285: 595-599.
17. Pryce, G. et al. 2005. Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J. Neuroimmunol. 165: 41-52.
18. Rostagno, A. et al. 2002. Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease. J. Biol. Chem. 277: 49782-49790.
19. Revesz,T. et al. 2002. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 12: 343-357.
20. Holton, J.L. et al. 2002. Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. J. Neuropathol. Exp. Neurol. 61: 254-267.
21. Revesz, T. et al. 2003. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J. Neuropathol. Exp. Neurol. 62: 885-898.
22. Esiri, M.M. & G.K. Wilcock. 1986. Cerebral amyloid angiopathy in dementia and old age. J. Neurol. Neurosurg. Psychiatry 49: 1221-1226.
23. Belza, M.G. & H. Urich. 1986. Cerebral amyloid angiopathy in Down's syndrome. Clin. Neuropathol. 5: 257- 260.
24. Premkumar, D.R. et al. 1996. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am. J. Pathol. 148: 2083-2095.
25. Chalmers, K., G.K.Wilcock & S. Love. 2003. APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol. Appl. Neurobiol. 29: 231-238.
26. Love, S. et al. 2003. APOE and cerebral amyloid angiopathy in the elderly. Neuroreport 14: 1535-1536.
27. Selkoe, D.J. et al. 1987. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 235: 873-877.
28. Uchida, K., H. Nakayama & N. Goto. 1991. Pathological studies on cerebral amyloid angiopathy, senile plaques and amyloid deposition in visceral organs in aged dogs. J. Vet. Med. Sci. 53: 1037-1042.
29. Walker, L.C. 1997. Animal models of cerebral beta-amyloid angiopathy. Brain Res. Brain Res. Rev. 25: 70-84.
30. Hendriks, L. et al. 1992. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat. Genet. 1: 218- 221.
31. Bornebroek, M., J. Haan & R.A. Roos. 1999. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): a review of the variety in phenotypic expression. Amyloid 6: 215-224.
32. Miravalle, L. et al. 2000. Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J. Biol. Chem. 275: 27110-27116.
33. Obici, L. et al. 2005. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann. Neurol. 58: 639-644.
34. Cabrejo, L. et al. 2006. Phenotype associated with APP duplication in five families. Brain 129: 2966-2976.
35. Yamada, M. et al. 1997. Association of presenilin-1 polymorphism with cerebral amyloid angiopathy in the elderly. Stroke 28: 2219-2221.
36. Mann, D.M. et al. 1997. Amyloid (Abeta) deposition in chromosome 1-linked Alzheimer's disease: the Volga German families. Ann. Neurol. 41: 52-57.
37. Crook, R. et al. 1998. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat. Med. 4: 452-455.
38. Houlden, H. et al. 2000. Variant Alzheimer's disease with spastic paraparesis and cottonwool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. Ann. Neurol. 48: 806-808.
39. Yamada, M. 2004. Cerebral amyloid angiopathy and gene polymorphisms. J. Neurol. Sci. 226: 41-44.
40. O'Donnell, H.C. et al. 2000. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N. Engl. J. Med. 342: 240-245.
41. Schneider, J.A. et al. 2007.Mixed brain pathologies account formost dementia cases in community-dwelling older persons. Neurology 69: 2197-2204.
42. Nicoll, J.A. et al. 2004. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol. Aging 25: 589-597; discussion 603-584.
43. Zlokovic, B.V. 2005. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28: 202- 208.
44. Lippa, C.F. & D.S. Knopman 2007. Dementia:many roads, but not built in a day. Neurology 69: 2193-2194.
45. Yamaguchi, H. et al. 1990. Immunoelectron microscopic localization of amyloid beta protein in the diffuse plaques of Alzheimer-type dementia. Brain Res. 508: 320-324.
46. Dickson, D.W. 1997. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56: 321-339.
47. McGowan, E. et al. 2005. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47: 191-199.
48. Kim, J. et al. 2007. Abeta40 inhibits amyloid deposition in vivo. J. Neurosci. 27: 627-633.
49. Van Broeckhoven, C. 1995. Presenilins and Alzheimer disease. Nat. Genet. 11: 230-232.
50. Murayama,O. et al. 1999. Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci. Lett. 265: 61-63.
51. Taddei, K. et al. 1998. Two novel presenilin-1 mutations (Ser169Leu and Pro436Gln) associated with very early onset Alzheimer's disease. Neuroreport 9: 3335-3339.
52. Castano, E.M. et al. 1996. The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. J. Biol. Chem. 271: 32185-32191.
53. Frangione, B. et al. 2001. Familial cerebral amyloid angiopathy related to stroke and dementia. Amyloid 8(Suppl 1): 36-42.
54. Dahme, E. & B. Schroder. 1979. [Congophilic angiopathy, cerebrovascular microaneurysms and cerebral hemorrhages in old dogs]. Zentralbl Veterinarmed A 26: 601-613.
55. Giaccone, G. et al. 1990. Cerebral preamyloid deposits and congophilic angiopathy in aged dogs. Neurosci. Lett. 114: 178-183.
56. Papaioannou, N. et al. 2001. Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques. Amyloid 8: 11-21.
57. Walker, L.C. et al. 1990. Amyloid in the brains of aged squirrel monkeys. Acta Neuropathol. 80: 381-387.
58. Yamaguchi, H. et al. 1992. Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am. J. Pathol. 141: 249-259.
59. Natte, R. et al. 1999. Ultrastructural evidence of early nonfibrillar Abeta42 in the capillary basement membrane of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type. Acta Neuropathol. 98: 577-582.
60. Jarrett, J.T., E.P. Berger & P.T. Lansbury Jr. 1993. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-4697.
61. Kimchi, E.Y. et al. 2001. Analysis of cerebral amyloid angiopathy in a transgenic mousemodel of Alzheimer disease using in vivomultiphotonmicroscopy. J.Neuropathol. Exp. Neurol. 60: 274-279.
62. Domnitz, S.B. et al. 2005. Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease. J. Neuropathol. Exp. Neurol. 64: 588-594.
63. Snow, A.D., J.P. Willmer & R. Kisilevsky. 1987. Sulfated glycosaminoglycans in Alzheimer's disease. Hum. Pathol. 18: 506-510.
64. Namba, Y. et al. 1991. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541: 163-166.
65. Abraham, C.R., D.J. Selkoe & H. Potter 1988. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52: 487-501.
66. Bauer, J. et al. 1991. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285: 111-114.
67. McGeer, P.L. et al. 1989. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107: 341-346.
68. McGeer, P.L. et al. 1994. Pathological proteins in senile plaques. Tohoku J. Exp. Med. 174: 269-277.
69. Verbeek, M.M. et al. 1994. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am. J. Pathol. 144: 104- 116.
70. Verbeek, M.M., P. Eikelenboom & R.M. de Waal 1997. Differences between the pathogenesis of senile plaques and congophilic angiopathy in Alzheimer disease. J. Neuropathol. Exp. Neurol. 56: 751-761.
71. Verbeek, M.M. et al. 1998. Distribution ofAbeta-associated proteins in cerebrovascular amyloid of Alzheimer's disease. Acta Neuropathol. 96: 628-636.
72. Schwab, C., M.Hosokawa & P.L.McGeer 2004. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp. Neurol. 188: 52-64.
73. Davis, J. et al. 2004. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem. 279: 20296-20306.
74. Fan, R., K. DeFilippis & W.E. Van Nostrand 2007. Induction of complement proteins in amouse model for cerebral microvascular A beta deposition. J. Neuroinflammation 4: 22.
75. McGeer, P.L. & E.G., McGeer 2001. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22: 799- 809.
76. Tenner, A.J. 2001. Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol. Aging 22: 849-861.
77. Wyss-Coray, T. et al. 2002. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. USA 99: 10837- 10842.
78. Maier, M. et al. 2008. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 28: 6333-6341.
79. Fonseca, M.I. et al. 2004. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosci. 24: 6457-6465.
80. Strittmatter,W.J. et al. 1993.Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90: 1977-1981.
81. Yamaguchi, H. et al. 1994. Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer beta-amyloid deposition. Acta Neuropathol. 88: 413-419.
82. Corder, E.H. et al. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
83. Strittmatter, W.J. & A.D. Roses. 1995. Apolipoprotein E and Alzheimer disease. Proc.Natl. Acad. Sci.USA 92: 4725- 4727.
84. Greenberg, S.M. et al. 1995. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 38: 254-259.
85. Greenberg, S.M. et al. 1996. Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 27: 1333- 1337.
86. Thal, D.R. et al. 2002. Two types of sporadic cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 61: 282-293.
87. Zhang, S.H. et al. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258: 468-471.
88. Games, D. et al. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373: 523-527.
89. Bales, K.R. et al. 1997. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17: 263-264.
90. Irizarry, M.C. et al. 2000. Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice. Acta Neuropathol. 100: 451-458.
91. Dodart, J.C. et al. 2002.Apolipoprotein E alters the processing of the beta-amyloid precursor protein in APP(V717F) transgenic mice. Brain Res. 955: 191-199.
92. Nilsson, L.N. et al. 2004. Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol. Aging 25: 1153-1167.
93. Hsiao, K. et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
94. Irizarry, M.C. et al. 1997. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56: 965-973.
95. Holtzman, D.M. et al. 2000. Apolipoprotein E isoformdependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97: 2892-2897.
96. Fagan, A.M. et al. 2002.HumanandmurineApoEmarkedly alters A betametabolism before and after plaque formation in amouse model of Alzheimer's disease. Neurobiol. Dis. 9: 305-318.
97. Xu, F. et al. 2008. Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice. J. Neurosci. 28: 5312-5320.
98. Nicoll, J.A. et al. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9: 448-452.
99. Ferrer, I. et al. 2004. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14: 11-20.
100. Masliah, E. et al. 2005. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64: 129-131.
101. Nicoll, J.A. et al. 2006. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol. 65: 1040-1048.
102. Holmes,C. et al. 2008. Long-termeffects ofAbeta42immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223.
103. Boche, D. et al. 2008. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131: 3299-3310.
104. Boche, D. et al. 2010. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol. 120: 13-20.
105. Orgogozo, J.M. et al. 2003. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54.
106. Cribbs, D.H. et al. 2003. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with betaamyloid. Int. Immunol. 15: 505-514.
107. Cribbs, D.H. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.CNSNeurol.Disord.Drug Targets 9: 207-216.
108. Weller,R.O.,D. Boche&J.A.Nicoll. 2009.Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol. 118: 87-102.
109. Boche, D. et al. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol. 120: 369-384.
110. Uro-Coste, E. et al. Cerebral amyloid angiopathy and microhemorrhages after amyloid beta vaccination: case report and brief review. Clin. Neuropathol. 29: 209-216.
111. Black, R.S. et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 24: 198-203.
112. Salloway, S. et al. 2009. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73: 2061-2070.
113. Serrano-Pozo, A. et al. 2010. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 133: 1312-1327.
114. Oddo, S. et al. 2004. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43: 321-332.
115. Pfeifer, M. et al. 2002. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298: 1379.
116. Racke, M.M. et al. 2005. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25: 629-636.
117. Wilcock, D.M. et al. 2007. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144: 950- 960.
118. Head, E. et al. 2008. A two-year study with fibrillar betaamyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J. Neurosci. 28: 3555- 3566.
119. Patton, R.L. et al. 2006. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol. 169: 1048- 1063.
120. Petrushina, I. et al. 2008. Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J. Neuroinflammation 5: 42.
121. Wilcock, D.M. et al. 2004. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 1: 24.
122. Wilcock, D.M. et al. 2006. Deglycosylated anti-amyloidbeta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci. 26: 5340-5346.
123. Karlnoski, R.A. et al. 2008. Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice. J. Neuroimmune Pharmacol. 3: 187- 197.
124. Thakker,D.R. et al. 2009. Intracerebroventricular amyloidbeta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc. Natl. Acad. Sci. USA 106: 4501-4506